Author:
Vlachostergios Panagiotis J.,Faltas Bishoy M.
Publisher
Springer Science and Business Media LLC
Reference167 articles.
1. Aragon-Ching, J. B. Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. Urol. Oncol. 35, 462–464 (2017).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
3. NIH. Cancer stat facts: bladder cancer. National Cancer Institute Surveillance, Epidemiology and End Results Program
https://seer.cancer.gov/statfacts/html/urinb.html
(2017).
4. Sridhar, S. S. Evolving treatment of advanced urothelial cancer. J. Oncol. Pract. 13, 309–315 (2017).
5. Sternberg, C. N. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J. Clin. Oncol. 19, 2638–2646 (2001).